Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy

Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.

[1]  S. Riddell,et al.  The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity , 2014, Cancer Immunology Research.

[2]  J. Yee,et al.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[4]  Christian Stemberger,et al.  Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. , 2014, Blood.

[5]  S. Riddell,et al.  Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. , 2006, Cancer research.

[6]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[7]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[8]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[9]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[10]  W. Uckert,et al.  Minimal Amino Acid Exchange in Human TCR Constant Regions Fosters Improved Function of TCR Gene-Modified T Cells , 2010, The Journal of Immunology.

[11]  Abigail Wacher,et al.  Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.

[12]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Grupp,et al.  Chimeric antigen receptor T-cell therapy for ALL. , 2014, Hematology. American Society of Hematology. Education Program.

[14]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[15]  B. Engels,et al.  Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette , 2008, Journal of Molecular Medicine.

[16]  I. Korndörfer,et al.  Improved affinity of engineered streptavidin for the Strep‐tag II peptide is due to a fixed open conformation of the lid‐like loop at the binding site , 2002, Protein science : a publication of the Protein Society.

[17]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[18]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[19]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[20]  C. Desmarais,et al.  Ultra-sensitive detection of rare T cell clones. , 2012, Journal of immunological methods.

[21]  T. Blankenstein,et al.  A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer , 2008, Proceedings of the National Academy of Sciences.

[22]  J. Buckner,et al.  Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.